Which of the following would you expect to happen if amino acids 579 to 582 (YIYV) in the PDGF-Beta receptor wereexchanged with amino acids 992 to 995 (YLIP) from the EGF receptor to give PDGF (YLIP) and EGF (YIYV) (Select allthat apply)?(A)(B)PDGF-BreceptorSrc$8&P 579P 581YIYVPI3KYP 740 YMDMNCK-a P 751 YVPMP 771 YMAPGAPNCK-BSHP2PLC-y PP 1009 YTAV1021 YIIPala845 YHAE992 YLIP P1045 YSSD1068 YINQ1086 YHNK1148 YQQDP1173 YLRVPPPPPEGFreceptorSTAT3/5PLC-yShcCblJAK2Grb2STAT3/5ShcSHP1PTP1

Name: Which of the following would you expect to happen if amino acids 579
Uploaded: 2024-03-20T06:42:55.000Z
Channel: Bartleby
Description: Which of the following would you expect to happen if amino acids 579 to 582 (YIYV) in the PDGF-Beta receptor wereexchanged with amino acids 992 to 995 (YLIP) from the EGF receptor to give PDGF (YLIP) and EGF (YIYV) (Select allthat apply)?(A)(B)PDGF-

The following are the receptors which expect to happen if amino acids 579 to 582 are;

Answered: 579 to 582 (YIYV) in the PDGF-Beta…

Science

Biology

579 to 582 (YIYV) in the PDGF-Beta receptor were eptor to give PDGF (YLIP) and EGF (YIYV) (Select all

Biomedical Instrumentation Systems

1st Edition

ISBN:9781133478294

Author:Chatterjee

Publisher:Chatterjee

Chapter17: Instrumentation In Intensive Care Units

Section: Chapter Questions

Problem 6P

See similar textbooks

Similar questions

What is the structural difference between normal EGFR and oncogenic receptor, e.g. ERbB? How does it affect its activity?
Describe how you would experimentally demonstrate that a specific G beta protein subunit is required for peptide agonist-stimulated increases in MAPK activity.
What do the cytoplasmic domain of a G protein-coupled receptor and the adaptor protein in the RTK pathway have in common?
Does adenylate cyclase become more active when the inhibitory (Gia) protein is mutated and increases its intrinsic GTPase activity?
Would the following alterations to Src be oncogenic? Explain. (a) The deletion or inactivation of the SH3 domain. (b) The mutation of Tyr 416 to Phe.
Explain why in cells that are genetically NF1–/–, basal levels of GTP-bound activated Ras are higher than normal and respond to growth factor stimulation by increasing rapidly to far higher levels.
In contrast to their similar brain abnormalities,newborn mice deficient in Apaf1 or caspase-9 have dis-tinctive abnormalities in their paws. Apaf1-deficient micefail to eliminate the webs between their developing digits,whereas caspase-9-deficient mice have normally formeddigits (Figure Q18–1). If Apaf1 and caspase-9 function inthe same apoptotic pathway, how is it possible for thesedeficient mice to differ in web-cell apoptosis?
How do you suppose the serine/threonine acetylase activity of YopJ might interfere with TAK1 activation?
Identify the two general functions of the proteins encoded bytumor-suppressor genes.
a.What would happen if IKKbeta did not phosphorylate IkappaB? b.Why is it so hard to make cytokine therapies? c.Why would you use the MyD88 independent pathway versus the MyD88 dependent pathway?
You decide to investigate cell signaling of a pair of newly identified GPCRs, GPCR-W and GPCR-Z. Each binds the same ligand, but activates different downstream heterotrimeric G-proteins that act on adenylyl cyclase. You discover that ligand binding has opposite effects on adenylyl cyclase activity for each receptor. GPCR-W causes an increase in adenylyl cyclase activity, while GPCR-Z causes a decrease in adenylyl cyclase activity. You obtain a cell line expressing GPCR-W, GPCR-Z, the relevant G-proteins, and adenylyl cyclase. There is baseline adenylyl cyclase activity producing a baseline amount of cAMP. You embark on a research project to characterize the following mutations in the components of the signaling pathway. 2. Will each of the following mutations increase or decrease the levels of cAMP inside the cell upon adding the ligand to the cell culture? A mutation in GPCR-W that prevents G-protein activation? A mutation in GPCR-Z that prevents G-protein activation? A mutation in…
You decide to investigate cell signaling of a pair of newly identified GPCRs, GPCR-W and GPCR-Z. Each binds the same ligand, but activates different downstream heterotrimeric G-proteins that act on adenylyl cyclase. You discover that ligand binding has opposite effects on adenylyl cyclase activity for each receptor. GPCR-W causes an increase in adenylyl cyclase activity, while GPCR-Z causes a decrease in adenylyl cyclase activity. You obtain a cell line expressing GPCR-W, GPCR-Z, the relevant G-proteins, and adenylyl cyclase. There is baseline adenylyl cyclase activity producing a baseline amount of cAMP. You embark on a research project to characterize the following mutations in the components of the signaling pathway. 2. Will each of the following mutations increase or decrease the levels of cAMP inside the cell upon adding the ligand to the cell culture? A mutation in Gi that prevents release of bound GDP. A mutation in Gs that prevents GTP hydrolysis. A mutation in Gi that…